ClinicalTrials.gg
CompletedNCT07697625Updated Nov 2, 2026

A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)

A Phase 1 interventional study of MK-4082 and Diltiazem in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Updated Nov 2, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Researchers are looking for new weight loss medicines for people with higher body weight. The trial medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a trial medicine to participants with a health condition, researchers first do trials in healthy participants to find a safe dose level (amount) of the trial medicine.

The goal of this study is to learn what happens to MK-4082 in a person's body over time. Researchers will compare what happens to levels of MK-4082 in people's blood when it is taken alone (Part 1, Period 1 and Part 2) and in combination with (Part 1, Period 2) another medicine called diltiazem. Researchers also want to learn about the safety of MK-4082 taken with and without diltiazem and if people tolerate them.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is in good health
  • (BMI) between 18 and 32 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a history of previous surgical treatment for obesity that may induce malabsorption, history of bowel resection >20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure for weight loss
  • Had a recent pancreatitis or has a history of pancreatitis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    MK-4082

    Participants will move sequentially through 2 periods in Part 1. In Period 1, participants will receive a single oral dose of MK-4082 on Day 1. In Period 2, participants will receive a single oral dose of MK-4082 on Day 1 plus oral diltiazem for multiple days. In Part 2 participants receive a single dose of MK-4082 or placebo.

    Drug: MK-4082 · Drug: Diltiazem · Drug: Rescue medication

Interventions

  • Oral administration

  • Oral administration

  • DrugRescue medication

    All participants will receive ondansetron as a rescue medication. Ondansetron is a medication used to prevent nausea or vomiting.

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of MK-4082

    Blood samples will be collected to determine the AUC0-∞ of MK-4082.

    Time frame: At designated timepoints (up to approximately 1 week postdose)

  2. Part 1: Maximum Plasma Concentration (Cmax) of MK-4082

    Blood samples will be collected to determine the Cmax of MK-4082.

    Time frame: At designated timepoints (up to approximately 1 week postdose)

  3. Part 1: Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 31 days

  4. Part 1: Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 17 days

Secondary outcomes

  1. Part 2: AUC0-∞ of MK-4082

    Blood samples will be collected to determine the AUC0-∞ of MK-4082.

    Time frame: At designated timepoints (up to approximately 1 week postdose)

  2. Part 2: AUC0-24 of MK-4082

    Blood samples will be collected to determine the AUC0-24 of MK-4082.

    Time frame: At designated timepoints (up to 24 hours postdose)

  3. Part 2: Cmax of MK-4082

    Blood samples will be collected to determine the Cmax of MK-4082.

    Time frame: At designated timepoints (up to approximately 1 week postdose)

  4. Part 2: Time to maximum plasma concentration (Tmax) of MK-4082

    Blood samples will be collected to determine the Tmax of MK-4082.

    Time frame: At designated timepoints (up to approximately 1 week postdose)

  5. Part 2: Plasma concentration 24 hours postdose (C24) of MK-4082

    Blood samples will be collected to determine the C24 of MK-4082.

    Time frame: 24 hours postdose

  6. Part 2: Apparent terminal half-life (t½) of MK-4082

    Blood samples will be collected to determine the t½ of MK-4082.

    Time frame: At designated timepoints (up to approximately 1 week postdose)

07

Study locations

1 site
  • Anaheim Clinical Trials ( Site 0001)
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2026 to primary completion in Oct 2026, 2 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jul 13, 2026
StartActual
Jul 20, 2026
Primary completionActual
Oct 6, 2026was Sep 2026
CompletionActual
Oct 6, 2026was Sep 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 2, 2026
Primary completion
Sep 28, 2026→Oct 6, 2026 (actual)
Nov 2, 2026
Study completion
Sep 28, 2026→Oct 6, 2026 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Completed
    Primary completion Sep 28, 2026→Oct 6, 2026 (now actual)
    Study completion Sep 28, 2026→Oct 6, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07697625
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Jul 20, 2026
Primary completion
Oct 6, 2026
Completion
Oct 6, 2026
Last update
Nov 2, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-4082

Start the discussion